SCHEMBL9611284

SCHEMBL9611284

CC(C)(C)OC(=O)N1CC(=O)C[C@H]1CCNC(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.51
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SYK P43405 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
KEAP1 Q14145 2/20 0.43
NFE2L2 Q16236 2/20 0.43
GAA P10253 1/20 0.42
FKBP1A P62942 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PREP P48147 2/20 0.41
PARP1 P09874 1/20 0.41
KLK7 P49862 1/20 0.41
KLK5 Q9Y337 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2707632 1.00 ABCB1 (0.51) ABCB1IDO1TDO2LMNASMN1; SMN2
SCHEMBL3977625 0.84 ABCB1 (0.51) ABCB1LMNASMN1; SMN2KEAP1NFE2L2
SCHEMBL9611281 0.83 ABCB1 (0.57) ABCB1IDO1TDO2LMNASMN1; SMN2
SCHEMBL2705981 0.83 ABCB1 (0.57) ABCB1IDO1TDO2LMNASMN1; SMN2
SCHEMBL29589878 0.81 NPSR1 (0.50) ABCB1IDO1SYKPREP
SCHEMBL4037581 0.80 ABCB1 (0.51) ABCB1IDO1TDO2LMNASMN1; SMN2
SCHEMBL7520525 0.80 ABCB1 (0.49) ABCB1SYKMAPTHTTKEAP1
SCHEMBL4037583 0.80 ABCB1 (0.51) ABCB1IDO1TDO2LMNASMN1; SMN2
SCHEMBL8257141 0.80 ABCB1 (0.47) ABCB1IDO1TDO2LMNASMN1; SMN2
SCHEMBL28795615 0.79 NR1D1 (0.46) ABCB1FKBP1AMEN1KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415486-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-04-09 US disclosed
US-8415486-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-04-09 US disclosed
US-20120135990-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2012-05-31 US disclosed
WO-2010138666-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135990-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 ABCB1 393/4885IDO1 792/4885TDO2 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.